--- title: Attovia Therapeutics (ATTO) Targets $200 Million IPO to Advance Next-Generation Biologics for Immune-Mediated Diseases description: Clinical-stage biotechnology company is leveraging its proprietary ATTOBODY platform to develop next-generation biologics targeting validated immune pathways across dermatology and inflammatory diseases. image: https://blog.ipoprophet.com/hubfs/Attovia%20Thumbnail.jpg --- [Skip to content](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/attovia-therapeutics-atto-targets-200-million-ipo-to-advance-next-generation-biologics-for-immune-mediated-diseases#main-content) [![IPO_PROPHET_BLUE logo](https://blog.ipoprophet.com/hs-fs/hubfs/IPO_PROPHET_BLUE%20logo.png?width=2973&height=302&name=IPO_PROPHET_BLUE%20logo.png)](https://www.IPOProphet.com) - [Login](https://app.ipoprophet.com/login) Open main navigation Close main navigation - [Login](https://app.ipoprophet.com/login) [Subscribe to our Newsletter](https://share.hsforms.com/1xXldKrGiQBCbNmtOz6j4Jwq3cu4) [Go Back to Home](http://www.ipoprophet.com/) [Go Back to Blog](http://www.ipoprophet.com/blog) Jul 31, 2026, 3:12:40 PM # Attovia Therapeutics (ATTO) Targets $200 Million IPO to Advance Next-Generation Biologics for Immune-Mediated Diseases ![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) Share: [facebook-f icon](http://www.facebook.com/share.php?u=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/attovia-therapeutics-atto-targets-200-million-ipo-to-advance-next-generation-biologics-for-immune-mediated-diseases) [linkedin-in icon](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/attovia-therapeutics-atto-targets-200-million-ipo-to-advance-next-generation-biologics-for-immune-mediated-diseases) [Twitter icon](https://twitter.com/intent/tweet?url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/attovia-therapeutics-atto-targets-200-million-ipo-to-advance-next-generation-biologics-for-immune-mediated-diseases) [pinterest-p icon](http://pinterest.com/pin/create/link/?url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/attovia-therapeutics-atto-targets-200-million-ipo-to-advance-next-generation-biologics-for-immune-mediated-diseases) [envelope icon](mailto:?body=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/attovia-therapeutics-atto-targets-200-million-ipo-to-advance-next-generation-biologics-for-immune-mediated-diseases) ![Attovia logo](https://blog.ipoprophet.com/hs-fs/hubfs/Attovia%20logo.png?width=372&height=162&name=Attovia%20logo.png) **Attovia Therapeutics (NASDAQ: ATTO)** has filed to raise approximately **$200 million** through an initial public offering of **12.5 million shares** priced between **$15.00 and $17.00 per share**, implying a midpoint offering size of **$200 million** and a fully diluted market capitalization of approximately **$616 million** at the midpoint. The offering is being led by **Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets, and LifeSci Capital.** Attovia is a clinical-stage biotechnology company developing next-generation biologics for immune-mediated diseases using its proprietary **ATTOBODY** platform. Unlike many early-stage biotechnology companies built around a single drug candidate, Attovia has rapidly assembled a pipeline of internally discovered therapeutics designed to improve upon existing standards of care by targeting commercially validated immune pathways while potentially offering greater efficacy, longer dosing intervals, and improved patient convenience. The company's lead candidate, **ATTO-1310**, targets **interleukin-31 (IL-31)**, commonly referred to as the "itch cytokine," for the treatment of chronic pruritic diseases including chronic pruritus, high-itch atopic dermatitis, cholestatic pruritus, and chronic kidney disease-associated pruritus. Early Phase 1 data demonstrated favorable tolerability, low immunogenicity, rapid itch relief, and pharmacokinetic characteristics that could support **once-quarterly subcutaneous dosing**, a potentially meaningful advantage over existing therapies. The company expects to initiate a Phase 2 study during the first half of 2027. Beyond its lead program, Attovia is advancing **ATTO-2306**, a bispecific biologic targeting both **IL-13 and IL-31** for atopic dermatitis and other inflammatory skin diseases, as well as **ATTO-1091**, a trispecific biologic targeting **TL1A, IL-23, and integrin α4β7** for inflammatory bowel disease. Both candidates are currently in IND-enabling studies, with Phase 1 clinical trials expected to begin during the first half of 2027. ![](https://blog.ipoprophet.com/hs-fs/hubfs/image-png-Jul-31-2026-07-05-50-6042-PM.png?width=687&height=332&name=image-png-Jul-31-2026-07-05-50-6042-PM.png) The company's underlying **ATTOBODY** platform represents a key differentiator. Built around biparatopic nanobody technology licensed from Alamar Biosciences, the platform is designed to rapidly generate highly potent mono-, bi-, and trispecific biologics capable of simultaneously targeting multiple disease pathways. Management believes this modular approach could accelerate drug discovery while improving potency, durability, and dosing convenience compared with conventional antibody therapies. Financially, Attovia remains a pre-commercial biotechnology company investing heavily in research and development. The company reported **2025 collaboration revenue of $1.35 million**, a **net loss of $60.6 million**, and held **$132.6 million in cash, cash equivalents, and marketable securities** as of March 31, 2026. Management also disclosed preliminary cash, cash equivalents, and marketable securities of approximately **$115.1 million** as of June 30, 2026. At the midpoint pricing assumption, the IPO is expected to generate approximately **$182.4 million** in net proceeds to support continued clinical development of **ATTO-1310**, **ATTO-2306**, **ATTO-1091**, and the broader research pipeline. ![Attovia Placard](https://blog.ipoprophet.com/hs-fs/hubfs/Attovia%20Placard.jpg?width=898&height=595&name=Attovia%20Placard.jpg) Since its founding in 2023, Attovia has raised approximately **$255.8 million** from leading life sciences investors including **Deep Track Capital, Frazier Life Sciences, Goldman Sachs Alternatives, and venBio**, providing significant institutional backing ahead of its public debut. **Attovia's investment thesis extends beyond any single drug candidate. The company's proprietary ATTOBODY platform, expanding pipeline, and focus on clinically validated immune pathways provide multiple opportunities for long-term value creation. As with most early-stage biotechnology companies, however, future valuation will largely depend on successful clinical execution, regulatory progress, and the ability to demonstrate meaningful differentiation from existing therapies.**   [IPOs](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/ipos), [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [Attovia Therapeutics](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/attovia-therapeutics) ## Related posts [![](https://blog.ipoprophet.com/hs-fs/hubfs/Braveheart%20Bio%20Thumbnail.jpg?height=200&name=Braveheart%20Bio%20Thumbnail.jpg)](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/braveheart-bio-brve-sets-terms-for-300-million-ipo-to-advance-next-generation-therapy-for-hypertrophic-cardiomyopathy) [IPOs](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/ipos), [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [Braveheart Bio](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/braveheart-bio) ## [Braveheart Bio (BRVE) Sets Terms for $300 Million IPO to Advance Next-Generation Therapy for Hypertrophic Cardiomyopathy](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/braveheart-bio-brve-sets-terms-for-300-million-ipo-to-advance-next-generation-therapy-for-hypertrophic-cardiomyopathy) ![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) Jul 31, 2026, 1:41:24 PM Braveheart Bio (NASDAQ: BRVE) has filed to raise approximately $300 million through an initial... [Read more](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/braveheart-bio-brve-sets-terms-for-300-million-ipo-to-advance-next-generation-therapy-for-hypertrophic-cardiomyopathy) [![](https://blog.ipoprophet.com/hs-fs/hubfs/Generate%20Biosciences%20Image.png?height=200&name=Generate%20Biosciences%20Image.png)](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/generate-biomedicines-sets-terms-for-400-million-ipo-as-asthma-focused-ai-biotech-advances-generative-protein-platform) [Nasdaq](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/nasdaq), [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [Generate Biomedicines](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/generate-biomedicines) ## [Generate Biomedicines Sets Terms for $400 Million IPO as Asthma-Focused AI Biotech Advances Generative Protein Platform](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/generate-biomedicines-sets-terms-for-400-million-ipo-as-asthma-focused-ai-biotech-advances-generative-protein-platform) ![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) Feb 23, 2026, 4:06:42 PM [Read more](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/generate-biomedicines-sets-terms-for-400-million-ipo-as-asthma-focused-ai-biotech-advances-generative-protein-platform) [![](https://blog.ipoprophet.com/hs-fs/hubfs/Kardigan%20Thumbnail.png?height=200&name=Kardigan%20Thumbnail.png)](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/kardigan-eyes-350-million-ipo-as-precision-cardiology-pipeline-advances-across-three-late-stage-programs) [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [Kardigan, Inc.](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/kardigan-inc) ## [Kardigan Eyes $350 Million IPO as Precision Cardiology Pipeline Advances Across Three Late-Stage Programs](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/kardigan-eyes-350-million-ipo-as-precision-cardiology-pipeline-advances-across-three-late-stage-programs) ![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) Jun 15, 2026, 4:47:17 PM Kardigan, Inc. (KARD) has filed for an initial public offering of 23.33 million shares at a price... [Read more](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/kardigan-eyes-350-million-ipo-as-precision-cardiology-pipeline-advances-across-three-late-stage-programs) [linkedin-in icon](https://www.linkedin.com/company/ipo-prophet-software/) [X Twitter icon](https://www.x.com/ipoprophet) --- [![IPO_PROPHET_WHITE-2](https://blog.ipoprophet.com/hs-fs/hubfs/IPO_PROPHET_WHITE-2.png?width=800&height=250&name=IPO_PROPHET_WHITE-2.png "IPO_PROPHET_WHITE-2")](http://www.ipoprophet.com) NONE OF THE CONTENT PUBLISHED ON THE WEBSITE OR MOBILE APP CONSTITUTES A RECOMMENDATION, SOLICITATION, ENDORSEMENT, OR OFFER BY IPO PROPHET™ OR ITS AFFILIATES TO BUY OR SELL ANY SECURITIES, FUTURES, OPTIONS, OR OTHER FINANCIAL INSTRUMENTS, OR PROVIDE ANY INVESTMENT ADVICE OR SERVICE. Copyright © 2025 ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Eric Friedman", "url" : "https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman" }, "dateModified" : "2026-07-31T19:12:40.629Z", "datePublished" : "2026-07-31T19:12:40.000Z", "headline" : "Attovia Therapeutics (ATTO) Targets $200 Million IPO to Advance Next-Generation Biologics for Immune-Mediated Diseases", "image" : [ "https://blog.ipoprophet.com/hubfs/Attovia%20Thumbnail.jpg" ], "mainEntityOfPage" : { "@id" : "https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/attovia-therapeutics-atto-targets-200-million-ipo-to-advance-next-generation-biologics-for-immune-mediated-diseases", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.ipoprophet.com/hubfs/IPO_PROPHET_BLUE%20logo-1.png" }, "name" : "ipoprophet.com" } } ```